. 2014 Apr;58(4):2067–2075. doi: 10.1128/AAC.00617-13

TABLE 2.

Parasitemia and maximum peaks of parasitemia in T. cruzi-infected mice treated with lychnopholide i.v. using different treatment schemes during acute infection^a

Treatment (dose [mg/kg])^d	Strain and treatment scheme^b
	CL strain, expt I		CL strain, expt II		Y strain, expt III		Y strain, expt IV
	Subpatent PAR/total^c	MPP ± SE (10⁴) (% reduction)^e	Subpatent PAR/total	MPP ± SE (10⁴) (% reduction)	Subpatent PAR/total	MPP ± SE (10⁴) (% reduction)	Subpatent PAR/total	MPP ± SE (10⁴) (% reduction)
Untreated	0/8	223.4 ± 40.8 (ND)	0/8	244.7 ± 24.3 (ND)	0/8	163.9 ± 12.9 (ND)	0/8	123.8 ± 7.8 (ND)
Benznidazole (50)	8/8	2.8 ± 0.9 (98.6)^A	8/8	1.2 ± 0.6 (99.2)^A	0/8	5.3 ± 1.3 (94.35)^A	7/8	2.2 ± 0.5 (97.9)^A,D
Free LYC (2)	1/8	88.6 ± 26.8 (56.3)^A,B,C	1/8	86.5 ± 27.4 (57.7)^A,B,C,D	0/8	90.6 ± 19.4 (37.85)^A,B,C	0/8	ND
LYC-PCL NC (2)	5/8	7.1 ± 2.7 (96.3)^A,C	8/8	3.3 ± 1.3 (98.3)^A,C,D	4/8	4.0 ± 1.7 (96.9)^A	6/8	5.3 ± 1.4 (94.9)^A,D
LYC-PLA-PEG NC (2)	ND	ND	8/8	1.5 ± 0.2 (99.3)^A	ND	ND	8/8	0.6 ± 0.1 (99.7)^A

Female Swiss albino mice (20 to 25 g) were infected with 10⁴ blood trypomastigotes/ml.

Treatment schemes are shown in more detail in Table 1.

Subpatent PAR/total, number of mice with a negative fresh blood examination during the acute phase of the infection divided by the total number of infected animals; MPP, maximum peak of parasitemia; ND, not determined.

Untreated, in this table the untreated group represents all the control groups, including untreated, unloaded PCL NC, unloaded PLA-PEG, and control solution.

The percent parasitemia reduction was based on untreated controls because there were no significant differences between the control groups (untreated, unloaded NC, and control solution). P values of <0.05 indicated significant differences and are denoted by superscript capital letters as follows: A, different from controls; B, different from LYC-PCL NC; C, different from BZ; and D, different from LYC-PLA-PEG).